KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

PURPOSE: Limited data are available about the influence of KIT and PDGFRA mutations on overall survival (OS) of patients with gastrointestinal stromal tumor (GIST) treated with adjuvant imatinib. PATIENTS AND METHODS: The Scandinavian Sarcoma Group XVIII/AIO multicenter trial accrued 400 patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Joensuu, Heikki, Wardelmann, Eva, Eriksson, Mikael, Reichardt, Annette, Hall, Kirsten Sundby, Schütte, Jochen, Cameron, Silke, Hohenberger, Peter, Sihto, Harri, Jost, Philipp J., Lindner, Lars H., Bauer, Sebastian, Nilsson, Bengt, Kallio, Raija, Pesonen, Tommi, Reichardt, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472091/
https://www.ncbi.nlm.nih.gov/pubmed/37014660
http://dx.doi.org/10.1158/1078-0432.CCR-22-3980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472091/
https://www.ncbi.nlm.nih.gov/pubmed/37014660
http://dx.doi.org/10.1158/1078-0432.CCR-22-3980

Ejemplares similares